TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01725113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: 3 times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: 3 times weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 3 times weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paricalcitol
Description: 3 times weekly
Study: NCT01792856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery-oriented intervention
Description: Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
Study: NCT02967198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT/US fusion
Description: Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound shear wave elastography
Description: ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
Study: NCT01857791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary, behavior modification
Study: NCT02345486

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiologically balanced fluid
Study: NCT00557973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 10 mg BID
Description: XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 20 mg BID
Description: XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP19986 SR1, 30 mg BID
Description: XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
Study: NCT03989960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA+SNIPPV
Description: The LISA+SNIPPV group receives PS by the way of invasive surfactant administration technique and selects nasal synchronized intermittent positive pressure ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional InSurE
Description: The traditional InSurE group receives intubation-surfactant- extubation technique and selects CPAP ventilation.
Study: NCT03552120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE
Description: MORE is a manualized integrative treatment strategy that targets transdiagnostic mechanisms in stress-related conditions. MORE is made up of three primary components: mindfulness training, cognitive restructuring, and savoring. Mindfulness training aims to increase attentional control to reduce cognitive bias toward negative information. Cognitive reappraisal promotes restructuring of maladaptive cognitions, which would otherwise intensify negative emotion and addictive behavior. Finally, MORE promotes savoring - mindful attention to and appreciation of pleasant events in life as a means of increasing positive emotion regulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Supportive psychotherapy is a form of non-directive talk therapy, which follows a Rogerian person-centered approach. The therapist's primary objectives during a session will be (1) to communicate unconditional positive regard for the participant, (2) to communicate engagement and empathic understanding, and (3) to mirror a participant's affect.
Study: NCT03717285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insert the UAS under direct vision
Description: Patients in this group，we use rigid ureteroscopy to insert the UAS under direct vision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insert the UAS under non direct vision
Description: Patients in this group，we insert the UAS by the experience of the surgeon and under non direct vision .
Study: NCT01752920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib low dose range
Description: Derazantinib was administered orally at dose levels from 25 mg QOD - 200 mg QD on a 28-day schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib middle dose range
Description: Derazantinib was administered orally at dose levels from 250 mg QD - 325 mg QD on a 28-day schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib high dose range
Description: Derazantinib was administered orally at dose levels from 400 mg QD - 425 mg QD on a 28-day schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Derazantinib at recommended phase 2 dose (RP2D)
Description: Derazantinib was administered orally at the recommended phase 2 dose of 300 mg QD on a 28-day schedule.
Study: NCT03096613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
Study: NCT01362114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIHOGAYONGGOLMORYU TANG EXTRACT GRAN
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
Study: NCT03139747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
Study: NCT03082391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy weight Mesh
Description: Patients will undergo ventral hernia repair with heavy weight mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heavy weight Mesh
Description: Patients will undergo ventral hernia repair with heavy weight mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medium weight Mesh
Description: Patients will undergo ventral hernia repair with medium weight mesh.
Study: NCT00861237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nux vomica (active comparator)
Description: Patients receive Nux vomica in a homeopathic potentiation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (placebo comparator)
Description: Patients receive Placebo looking similar to active drug
Study: NCT01470794

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: All patients will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antifungal 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, patients will begin courses of oral Toca FC at pre-specified intervals, depending on cohort, during the approximately 30 week study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Study: NCT00548353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK3207
Description: M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
Study: NCT04460352

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant radiotherapy (arm A)
Description: 1.8 Gy fractions 5 days per week in 23 fractions to a total dose of 41.4 Gy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin, paclitaxel
Description: Carboplatin AUC 2 + Paclitaxel 50mg/m2 weekly x 5 (day 1, 8, 15, 22, 29), starting same day as radiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy performed within 8 weeks after termination of chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (arm B)
Description: Two alternative schemes:~1. 1.8 Gy fractions five days per week in 28 fractions to a total dose of 50.4 Gy.~2. 2.0 Gy fractions five days per week in 25 fractions to a total dose of 50 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, paclitaxel
Description: Carboplatin AUC 2 + Paclitaxel 50mg/m2 on day 1 weekly during the full course of radiotherapy (5 weeks or 6 weeks, depending on the radiotherapy regimen used).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, paclitaxel
Description: Cisplatin 75mg/m2 on the first day of weeks 1 and 5 + 5-fluorouracil 1000 mg/m2/day by continuous infusion on the first four days of weeks 1 and 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, calcium folinate, 5-fluorouracil
Description: FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Esophagectomy only in case of residual or recurrent locoregional cancer.
Study: NCT04427696

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic walking intervention
Description: Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic walking intervention
Description: Walking exercise is self-controlled and tracked by daily dairy. All of the participants are obligated to record the start and end time of walking every day. And pedometers will be used for tracking walking steps including heart rate and calories. We plan to use pedometer in our study, which was reported the most accurate pedometer and suitable for scientific research. For the ones who are in the control group, they have to keep sedentary lifestyle, and no regular walking exercise, and they are agree to be in the comparable members in our study.
Study: NCT00860106

Intervention type: OTHER
Group type: OTHER
Intervention: ED, DDimers and phone follow up
Description: ED score, DDimers level and phone questionnary
Study: NCT00541281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 35mg/m² on day 2 and 9 (21days in a cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 35mg/m² on day 2 and 9 (21days in a cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estramustine
Description: 140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 2x5 mg a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 2x5 mg a day
Study: NCT04504864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose aspirin
Description: 50mg aspirin is used to prevent recurrent stroke.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional-does aspirin
Description: 100mg aspirin is used to prevent recurrent stroke.
Study: NCT03979677

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modifications
Description: Written suggestions on common migraine triggering food/beverages to avoid, restful sleep tips, exercise suggestions, and eating set mealtimes will be provided as the intervention.
Study: NCT00653497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Arthritis Foundation Aquatics Program~* community-based aquatic exercise program~* participants asked to attend 2 classes per week for 20 weeks~* each class 45-60 minutes in duration
Study: NCT01077713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 60mg/m2 on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200mg/m2 on days 1-8 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 on days 1-8 of each 3 week cycle
Study: NCT05245981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRI.MAG 2
Description: Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.
Study: NCT03718156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREPARED Trial Intervention
Description: Nursing staff members will be trained to adjust the therapeutic nursing plans (TNP) for residents enrolled in the study, as follows: 1) by providing optimal stimulation (surveying the use of eyeglasses and hearing aids, the room lighting and space organization; orienting the resident to time and space; and stimulating the resident using familiar objects, photos, and life histories); and 2) by assessing the presence of 4 modifiable delirium risk factors (antipsychotic use, sensory impairment, restraint use, and dehydration) and taking specific actions once a given risk factor is identified. For instance, if physical restraints are used, the TNP will require that they are to be removed during care when a caregiver is present (nail care, feeding, and wound care).
Study: NCT00736528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 05 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 15 mg BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04447943
Description: 45mg BID for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14 days
Study: NCT00467584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Aspirin (1300 mg/day)
Description: 1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Aspirin (162 mg/day)
Description: 162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
Study: NCT02762565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEFS system (Product Name: Intelligent Breast Exam™ or iBE™
Study: NCT02579083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB66
Description: 10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB66
Description: 10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
Study: NCT06224582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yinxingmihuan oral solution
Description: Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
Study: NCT00685971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5000 IU of cholecalciferol
Description: 5 drops taken once daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 drops once daily for 12 weeks
Study: NCT02947113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiotherapy
Description: Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
Study: NCT05494554

Intervention type: DEVICE
Intervention: Changing mechanical ventilation mode
Description: On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.

Intervention type: DEVICE
Intervention: Changing mechanical ventilation mode
Description: On the 2nd day of intensive care hospitalization, while under deep sedation and in the controlled mode (VCV or PRVC) and in the supine position, the ventilator in the VCV mode was switched to PRVC mode for 60 minutes without changing any of the set ventilator settings (RR, PEEP, TV, I:E ratio). Likewise, if it is in PRVC mode, it is also switched to VCV mode for 60 minutes. MP values were calculated from the minute respiratory parameters of all patients with the MP formulas defined in the software.
Study: NCT01478633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
Study: NCT01313728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone plus Tretinoin Gel
Description: Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin Gel
Description: Tretinoin gel applied once daily to the assigned side of the face for 2 weeks